Patients responding to an Accenture survey said drugmakers don't engage patients as well as advocacy groups do and said drugmakers should partner with such groups. Accenture surveyed 4,000 patients in the US and Europe who had rheumatoid arthritis, migraines or chronic lymphocytic leukemia, and 84% supported the idea of drugmakers and advocacy groups working together.
Patients say pharma's engagement efforts falling short
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.